CBLL - ceribell.com Long-Term Liabilities to Capital

Brandmark of CeriBell EEG (CBLL)

This price chart, serving as confirmation of the market valuation, demonstrates the price action of CeriBell, Inc. (CBLL), which generates revenue from the sale and leasing of AI systems for brain activity monitoring and EEG headsets. The long-term debt-to-equity ratio stands at 0.16. Management is effectively scaling the equipment fleet across US intensive care units, ensuring transparent growth. Meanwhile, the company adheres to basic eco-compliance by optimizing cloud computing and office processes.

CBLL - CeriBell Inc Long-Term Debt to Equity over the range 10/12/2024 - 10/28/2026
Core merchandise of CeriBell

Transparency of the financing structure is critical for conservative investors to assess business resilience against market shocks. This long-term debt-to-equity ratio measures the proportion of long-term liabilities relative to equity, determining the degree of financial leverage and the risk of insolvency. For CeriBell, Inc. (CBLL), which is developing cloud-based rapid EEG for intensive care units, this balance reveals the extent to which the technological platform's expansion relies on borrowed funds.

Competitor analysis

Long-Term Debt to Capital Ratio Biogen Inc|Neurocrine Biosciences Inc - Long-Term Debt to Capital|Long-Term Liabilities to Capital Regencell Corp RGC|Long-Term Debt to Equity Ratio AXSM (Axsome Therapeutics)|acadia-pharm.com - Long-Term Debt to Capital|Long-Term Debt to Equity Xenon (XENE)|VKTX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity SUPN|Catalyst Corp (CPRX) - Long-Term Liabilities to Capital|Long-Term Debt to Capital DNLI|Long-Term Debt to Equity Ratio harmonybiosciences.com|Biohaven - Long-Term Debt to Capital|Long-Term Liabilities to Capital AMLX (Amylyx Pharmaceuticals Inc)|Long-Term Debt to Equity Trevi Pharma|Long-Term Debt to Capital Coefficient Praxis Corp PRAX|Long-Term Debt to Capital AVXL (Anavex Life Sciences)|PRTA - Ratio of Long-Term Indebtedness to Capital|alector.com (ALEC) - Long-Term Debt to Capital|Annexon Biosciences (ANNX) - Long-Term Debt to Equity|Long-Term Debt to Capital OMER (Omeros Corp)|Long-Term Liabilities to Capital NGNE|Long-Term Debt to Equity AC Immune (ACIU)|Long-Term Debt to Equity VYGR (voyagertherapeutics.com)|Long-Term Debt to Equity Neumora Therapeutics, Inc. NMRA|SCLX - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Tevogen Bio Holdings, Inc. (TVGN)|ACOG - Long-Term Debt to Capital Coefficient|Cognition Therapeutics - Long-Term Debt to Capital|IKT (inhibikase.com) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Cassava Sciences (SAVA)|Long-Term Debt to Capital Ratio Assertio Therapeutics|Long-Term Debt to Capital COYA (Coya Therapeutics, Inc.)|Long-Term Debt to Equity Ratio vistagen.com VTGN|Long-Term Debt to Equity Ratio OVID|Ratio of Long-Term Indebtedness to Capital acumenpharm.com ABOS|CRVO: Long-Term Debt to Capital|ATHE - Long-Term Debt to Equity Ratio|clene.com (CLNN) - Long-Term Debt to Capital|PEPG (PepGen) - Long-Term Debt to Equity|Long-Term Debt to Equity Jupiter Neurosciences Inc|Long-Term Debt to Equity RLMD|Long-Term Debt to Equity Annovis Bio (ANVS)|Long-Term Debt to Equity GRCE (gracetx.com)|AIFF - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio ANEW Medical KLTO|NRSN (NeuroSense Therapeutics, Ltd.) - Long-Term Debt to Capital|revivapharma.com (RVPH) - Long-Term Liabilities to Capital|MTVA: Long-Term Debt to Equity Ratio|NRXS (NeurAxis Inc.) - Long-Term Debt to Capital|HSDT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PASG|Neuphoria Therapeutics Inc. - Long-Term Debt to Equity|Long-Term Liabilities to Capital minervaneurosciences.com (NERV)|Athira Pharma - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Addex Therapeutics Ltd. ADXN|ALZN (Alzamend) - Long-Term Debt to Capital|CYCN: Long-Term Liabilities to Capital|Long-Term Debt to Equity protagenic.com PTIX|Pasithea Therapeutics Corp. (KTTA) - Long-Term Debt to Capital Coefficient|CRGT: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Avenue Therapeutics Inc.|Long-Term Debt to Capital Brainstorm Cell Therapeutics, Inc. (BCLI)|Long-Term Debt to Equity Cara Therapeutics Inc (CARA)|CHRO: Long-Term Debt to Capital|Eliem Therapeutics, Inc. - Long-Term Liabilities to Capital|ITCI - Long-Term Debt to Equity|LBPH: Long-Term Debt to Equity|Marinus (MRNS) - Long-Term Debt to Equity|Long-Term Debt to Equity NKGen Biotech Corp|NRBO - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient sagerx.com|SNPX (Synaptogenix) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital TRVN (Trevena Inc.)|VIGL - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio Anew Medical Inc. WENA|CERE: Long-Term Debt to Capital